News

Early Invasive Intervention for Atrial Fibrillation may Improve Patient Outcomes and Provide a Better Quality of Life

November 16, 2020

Doctors from the Montreal Heart Institute (MHI) presented new data today at the American Heart Association Late-Breaking Scientific Sessions. Simultaneously published in the New England Journal of Medicine, the data shows that catheter ablation as first-line treatment may be better than antiarrhythmic drugs in preventing the recurrence of abnormal heart rhythm (atrial tachyarrhythmia, atrial fibrillation), and improve patient well-being.

Read more

CQDM funds the development of a novel artificial intelligence tool for cardiovascular clinical trials

November 5, 2020

A collaboration between Perceiv AI, DalCor Pharmaceuticals and the Montreal Heart Institute

The CQDM is pleased to announce the launch of a $600,000 collaborative project in biopharma and artificial intelligence (AI) to develop an AI-driven precision medicine tool.

Read more

Common hormone could provide the answer to treating atrial fibrillation

November 5, 2020

Researchers from University of Montreal, Oxford University, Baylor College of Medicine and the University of Melbourne make potential game-changing discovery on calcitonin

New research published today in Nature1 shows that calcitonin, a well-recognized thyroid hormone that helps regulate bone mass and collagen production, is also produced by cells in the heart. This discovery could hold the key to developing new treatments for people with atrial fibrillation (AF), a common and quite problematic heart rhythm disorder.

Read more